Phytochemical Analysis and Understanding the Antioxidant and Anticancer Properties of Methanol Extract from Litsea glutinosa: In Vitro and In Vivo Studies

The genus Litsea: A comprehensive review of traditional uses, phytochemistry, pharmacological activities and other studies

ETHNOPHARMACOLOGICAL RELEVANCE

The genus L. has high medicinal value and has traditional been used to treat a variety of gastrointestinal disorders, as well as diabetes, edema, colds, arthritis, asthma, and traumatic injuries.

AIM OF THE REVIEW

This work addresses the missing information by conducting a comprehensive analysis of the traditional uses, chemical components, and pharmacological applications of the more reported species of the genus L. The origin of the genus, its toxicology, and the use of classical therapies in modern medicine were also discussed. It provides references for historical evidence, resource development, and medical research on the genus.

METHOD

ology: Data about the genus L. were gathered via Web of Science, PubMed, Science Direct, Google Scholar, Connected Papers, China National Knowledge Infrastructure (CNKI), electronic ancient books and local chronicles. The WFO Plant List (wfoplantlist.org) and Flora of China (www.iplant.cn) confirmed L.'s Latin name, and the species information. The program ChemBioDraw Ultra 14.0 was used to create the molecular structures of the compounds that were displayed in the text.

RESULT

Currently, at least 740 constituents have been isolated and identified from L. These include 9 groups of chemicals, such as flavonoids, alkaloids, and terpenoids. They have been shown to have over 20 biological properties in vivo and in vitro, such as antibacterial, anti-inflammatory, and anti-oxidant effects.

CONCLUSION

Based on pharmacological investigations, chemical components, and traditional folk applications, L. is considered a medicinal plant having a variety of pharmacological actions. However, although the pharmacological activity of the L. genus has been preliminary demonstrated, most have only been assessed using simple in vitro cell lines or animal disease models. In order to fully elucidate the pharmacological activity and mechanisms of L., future studies should be conducted in a more comprehensive clinical manner.

Phytochemicals targeting epidermal growth factor receptor (EGFR) for the prevention and treatment of HNSCC: A review

Head and neck squamous cell carcinoma (HNSCC) develops from the mucosal epithelium of the oral cavity, pharynx, and larynx, and is the most common malignancy of the head and neck, the incidence of which continues to rise. The epidermal growth factor receptor is thought to play a key role in the pathogenesis of HNSCC. Inhibition of epidermal growth factor receptor has been identified as an effective target for the treatment of HNSCC. Many phytochemicals have emerged as potential new drugs for the treatment of HNSCC. A systematic search was conducted for research articles published in PubMed, and Medline on relevant aspects. This review provides an overview of the available literature and reports highlighting the in vitro effects of phytochemicals on epidermal growth factor in various HNSCC cell models and in vivo in animal models and emphasizes the importance of epidermal growth factor as a current therapeutic target for HNSCC. Based on our review, we conclude that phytochemicals targeting the epidermal growth factor receptor are potentially effective candidates for the development of new drugs for the treatment of HNSCC. It provides an idea for further development and application of herbal medicines for cancer treatment.

Hepatoprotective potency of Litsea glutinosa (L.) C.B. Rob. leaf methanol extract on H2O2-induced toxicity in HepG2 cells

ETHNOPHARMACOLOGICAL RELEVANCE

Leaves of Litsea glutinosa (L.) (Lauraceae) are traditionally used to treat hepatitis and liver injury by Bangladeshi folks. However, the hepatoprotective study of leaves of L. glutinosa has not been supported by any research.

AIM OF THE STUDY

To evaluate the antioxidant and hepatoprotective effects of leaves of methanol extract of L. glutinosa using the HepG2 cell line. Phytochemicals were identified with the help of a GC-MS study followed by In-silico docking of the promising compounds to justify our hepatoprotective effect.

MATERIALS & METHODS

The dried leaves of L. glutinosa (LGAO) were extracted by Soxhlet using methanol as solvent. Antioxidant effects were investigated using Superoxide dismutase (SOD), Reduced glutathione (GSH), Glutathione peroxidase (GPx), and Malondialdehyde (MDA) in HepG2 cells against H₂O₂ intoxicated group. The In-vitro hepatoprotective effect of LGAO (100 μg/ml) was determined in HepG2 cells as compared with the Silymarin-treated standard group (100 μg/ml) along with morphological changes of cells. Twelve numbers of phytochemicals were identified by GC-MS study. In-silico studies are performed for their inhibitory effects against Peroxisome proliferator-activated receptor alpha (PPAR-α) and Transforming growth factor-beta1 (TGF-β1) using AUTODOCK Tools-1.5.6 and Discovery studio 4.0.

RESULTS

Methanol extract of L. glutinosa possesses (LGAO) significant (p < 0.0001) increase in SOD, GSH, and GPx levels and a decrease in MDA as compared with the control one. MTT assay in HepG2 cells showed a significant (p < 0.0001) increase in the percentage of cell viability in LGAO and Silymarin-treated group i.e., 71.98%, 88.59% respectively as compared with the H₂O₂ intoxicated group alone i.e., 22.74%. Restoration of cell architecture in HepG2 cells was obtained by the LGAO and Silymarin-treated group treated with H₂O₂. Further, the In-silico study of Neophytadiene compound showed the highest docking score -10.2 and -8.6 towards receptors.

CONCLUSION

Methanol extract of leaves of L. glutinosa showed potential hepatoprotective effect In-vitro which justified our traditional claim. The presence of phytochemical Neophytadiene may be responsible for the said effect. Furthermore, molecular docking scores were consistent with the In-vitro results. They targeted the substantial inhibitory effects of Litsea glutinosa against receptors to establish the correlation between experimental and theoretical results.

A Potential Link Between Visceral Obesity and Risk of Alzheimer's Disease

Alzheimer's disease (AD) is the most common type of dementia characterized by the deposition of amyloid beta (Aβ) plaques and tau-neurofibrillary tangles in the brain. Visceral obesity (VO) is usually associated with low-grade inflammation due to higher expression of pro-inflammatory cytokines by adipose tissue. The objective of the present review was to evaluate the potential link between VO and the development of AD. Tissue hypoxia in obesity promotes tissue injury, production of adipocytokines, and release of pro-inflammatory cytokines leading to an oxidative-inflammatory loop with induction of insulin resistance. Importantly, brain insulin signaling is involved in the pathogenesis of AD and lower cognitive function. Obesity and enlargement of visceral adipose tissue are associated with the deposition of Aβ. All of this is consonant with VO increasing the risk of AD through the dysregulation of adipocytokines which affect the development of AD. The activated nuclear factor kappa B (NF-κB) pathway in VO might be a potential link in the development of AD. Likewise, the higher concentration of advanced glycation end-products in VO could be implicated in the pathogenesis of AD. Taken together, different inflammatory signaling pathways are activated in VO that all have a negative impact on the cognitive function and progression of AD except hypoxia-inducible factor 1 which has beneficial and neuroprotective effects in mitigating the progression of AD. In addition, VO-mediated hypoadiponectinemia and leptin resistance may promote the progression of Aβ formation and tau phosphorylation with the development of AD. In conclusion, VO-induced AD is mainly mediated through the induction of oxidative stress, inflammatory changes, leptin resistance, and hypoadiponectinemia that collectively trigger Aβ formation and neuroinflammation. Thus, early recognition of VO by visceral adiposity index with appropriate management could be a preventive measure against the development of AD in patients with VO.

The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity

Lung cancer is the second most commonly diagnosed cancer in the world. In terms of the diagnosis of lung cancer, combination carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125) detection had higher sensitivity, specificity, and diagnostic odds ratios than CEA detection alone. Most individuals with elevated serum CA125 levels had lung cancer that was either in stage 3 or stage 4. Serum CA125 levels were similarly elevated in lung cancer patients who also had pleural effusions or ascites. Furthermore, there is strong evidence that human lung cancer produces CA125 in vitro, which suggests that other clinical illnesses outside of ovarian cancer could also be responsible for the rise of CA125. MUC16 (CA125) is a natural killer cell inhibitor. As a screening test for lung and ovarian cancer diagnosis and prognosis in the early stages, CA125 has been widely used as a marker in three different clinical settings. MUC16 mRNA levels in lung cancer are increased regardless of gender. As well, increased expression of mutated MUC16 enhances lung cancer cells proliferation and growth. Additionally, the CA125 serum level is thought to be a key indicator for lung cancer metastasis to the liver. Further, CA125 could be a useful biomarker in other cancer types diagnoses like ovarian, breast, and pancreatic cancers. One of the important limitations of CA125 as a first step in such a screening technique is that up to 20% of ovarian tumors lack antigen expression. Each of the 10 possible serum markers was expressed in 29-100% of ovarian tumors with minimal or no CA125 expression. Therefore, there is a controversy regarding CA125 in the diagnosis and prognosis of lung cancer and other cancer types. In this state, preclinical and clinical studies are warranted to elucidate the clinical benefit of CA125 in the diagnosis and prognosis of lung cancer.